Concerns: 1) Old board members 2) where is OL banking? 3) no succession plan for Carter 4) just over 8% ROI for 2013 and probably not much better for 2014. 5) expenses high for the deposits/loans they carry 6) company may too concentrated in the family for the board to be independent 7) possible family dynasty in the making and that would be a deal breaker. Any opinions out there?
Read the article on Motley Fool. Seriously, almost $1/2 million in personal flights last year??? I think I might just show up at the annual meeting!! I do have stock in this criminal enterprise, and I am sure I shouldn't.
Been a customer for years of JOSB and was on a mens shopping forum when someone said they had ordered on-line from JOSB and when they received thier confirmation e-mail they had been charged $18 for handling. I didn't believe that until I checked several of my recent orders and found the same thing was done to me. The charge was added after I had submitted the order! They have lost my future business.
HR just reported slightly higher 3rd qtr. profits and is still far beyond its historical lows. The governmnet is not going to stop Medicare reimbursements, so frankly I don't get the price of this stock. Haven't owned HR in about tthree years and thinking about getting back in.
I've owned VNQ in the past and sold out a few months back since I could not justify its PE, I will buy it back if anyone can convice me it's the way to go in the 34 to 36 range.
Big pharma will be interested in this new hair compound once LUNA takes it into a human trial. Once safety is established (human toxicities uncovered etc.) then with the current hair growth market estimated over 10 billion (inclding scalp procedures and who really how much homeopathic crap is being sold on late night TV). Big pharma at that point , which could easily be in 2009, would pay up to $30,000,000 to take it into phase 2 trials. If LUNA caould show statistical effect in a phase 2 trial then the money would go to at least $60,000,000 plus royalty fees upon succesful phase 3's and FDA approval. This could be huge.
I see where two insiders bought in Jan in the high 30's. What do you think they saw in Jan to make them buy? Any thoughts?